Emcure Pharmaceuticals Limited promoters have submitted a declaration to stock exchanges under Regulation 31(4) of the SEBI Takeover Regulations for the financial year ended March 31, 2026. The disclosure confirms that no new encumbrances were created on the equity shares held by the promoters during the year. The filing was submitted to both the National Stock Exchange and BSE Limited.
The declaration was submitted by promoters Satish Mehta, Sunil Mehta, Samit Mehta and Namita Thapar. Satish Mehta is the Managing Director and CEO of Emcure Pharmaceuticals, while Samit Mehta, Sunil Mehta and Namita Thapar serve as Whole-time Directors. They stated that neither they nor the persons acting in concert with them had directly or indirectly encumbered their equity holdings in Emcure Pharmaceuticals during the fiscal year ended March 31, 2026.
The filing disclosed one existing encumbrance carried forward from the prior year. Promoter group member Smita Paresh Shah had pledged 60,000 equity shares during the financial year 2024-25. These shares remained under pledge as of March 31, 2026. No other promoter or promoter group entity reported any encumbrance.
The declaration covers four individual promoters and 37 promoter group entities. The promoter group includes corporate entities such as Thapar Ventures Private Limited, Incredible Ideas Private Limited, Heritage Pharma Holdings Inc. and A vet Lifesciences Private Limited. Multiple trusts, including Indus Trust, Unity Trust, Tulsi Trust and Cayuga Trust, are also part of the promoter group.
Emcure Pharmaceuticals has met the annual disclosure requirement under the SEBI Takeover Regulations through this submission. The promoters' shareholding remained free of new pledges or liens during the fiscal year. The only encumbrance continues to be the previously disclosed pledge of 60,000 shares held by Smita Paresh Shah. The disclosure was signed by all four promoters and was dated April 2, 2026.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.